Lophius' current and future portfolio of diagnostic solutions relies on and is constantly fed by the identification of novel disease-relevant biomarkers secreted by specifically stimulated cells, to detect infections or determine the disease status.

Development process for the identification and validation of biomarkers for diagnostic purposes at Lophius

One core competence of Lophius lies in the identification and validation of biomarkers produced by pathogen-specific immune cells representing an infection or disease state. To stimulate biomarker production of such specific immune cells in a blood sample, suitable antigens of the respective pathogen need to be identified and produced according to the highest quality standards (to avoid unspecific stimulation by contaminations).
Disease-specific biomarkers are then identified by bioinformatics analysis of biomarker patterns, comparing unstimulated and stimulated blood samples of suitable donors. Last but not least, the best-fitting read-out system is chosen for final diagnostic biomarker validation with relevant clinical samples.

Using Lophius' approach, unsolved clinical challenges presenting a high medical need can be addressed: this includes the detection of an active treatment-requiring disease status for infections like TB, or the monitoring of the status of autoimmune or inflammatory diseases if T cells are involved like for multiples sclerosis. An additional application is the analysis of immune responses following vaccination or T cell therapy.

This function requires IE9 or higher.
You can update your browser under: